Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease

Inclusion Criteria: * Weight between 50 and 120 kg; * Karnofsky performance status (KPS) ≥70%; * Confirmed diagnosis of sickle cell disease with βS/βS or βS/β0 or βS/β+ genotype; * Must have had one or more of the following events in the 2 year period preceding enrollment: * History of ≥2 severe vaso-occlusive pain crises (VOC) (or at least two episodes in the year preceding the setting up of regular transfusion protocol). A severe VOC is defined as an episode of pain lasting more than 2 hours severe enough to require care at a medical facility. * History of ≥1 episodes of acute chest syndrome despite the institution of supportive care measures (i.e. asthma therapy and/or hydroxyurea) * Clinically significant neurological event (stroke) or any neurological deficit lasting 24 hours. A stroke is defined as a sudden neurological change lasting more than 24 hours that is accompanied by cerebral magnetic resonance imaging (MRI) changes. * Prior treatment with regular RBC transfusion therapy, defined as receiving ≥8 transfusions per year for \>1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome) * Osteonecrosis of two or more joints; * Anti-erythrocyte alloimmunization (\>2 antibodies); * Presence of sickle cell cardiomyopathy documented by Doppler echocardiography; * Presence of any significant cerebral abnormality such as stenosis or occlusions on magnetic resonance imaging (MRA) * Meet current eligibility require…